Profile data is unavailable for this security.
About the company
Fuji Pharma Co., Ltd. is a Japan-based company mainly engaged in the manufacture and sale of medical products. The Company is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.
- Revenue in JPY (TTM)44.56bn
- Net income in JPY6.36bn
- Incorporated1965
- Employees1.62k
- LocationFuji Pharma Co Ltd6FIzumidate Bujin Tori, 5-7, Samban-choCHIYODA-KU 102-0075JapanJPN
- Phone+81 335563344
- Fax+81 335564455
- Websitehttps://www.fujipharma.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Stella Pharma Corp | 284.89m | -726.61m | 16.95bn | 44.00 | -- | 5.50 | -- | 59.49 | -22.94 | -22.94 | 8.91 | 90.49 | 0.061 | 0.0433 | 2.59 | 6,474,773.00 | -15.55 | -22.50 | -16.34 | -24.83 | 84.75 | -- | -255.05 | -488.65 | 17.82 | -563.58 | 0.217 | -- | 17.65 | -- | 1.94 | -- | -5.87 | -- |
CellSeed Inc | 199.47m | -957.04m | 17.02bn | 35.00 | -- | 7.76 | -- | 85.31 | -30.72 | -30.72 | 6.40 | 63.29 | 0.0892 | 1.65 | 7.91 | 5,699,172.00 | -42.79 | -49.69 | -46.02 | -54.55 | 55.38 | 63.66 | -479.79 | -428.62 | 16.42 | -5,460.76 | 0.0651 | -- | 50.39 | -28.62 | -11.43 | -- | 80.73 | -- |
CanBas Co Ltd (Parent) | 0.00 | -1.21bn | 17.24bn | 11.00 | -- | 6.94 | -- | -- | -67.63 | -67.63 | 0.00 | 129.88 | 0.00 | -- | -- | 0.00 | -53.54 | -62.25 | -56.62 | -70.91 | -- | -- | -- | -2,015.62 | 25.09 | -- | 0.00 | -- | -- | -- | 2.77 | -- | -- | -- |
TAIKO PHARMACEUTICAL CO LTD | 6.28bn | -2.34bn | 18.33bn | 208.00 | -- | 2.25 | -- | 2.92 | -46.93 | -46.93 | 125.40 | 160.66 | 0.434 | 1.69 | 2.94 | 30,201,920.00 | -16.12 | -- | -19.68 | -- | 55.73 | -- | -37.15 | -- | 2.83 | -- | 0.2166 | -- | 21.43 | -- | 26.23 | -- | -- | -- |
Oncolys Biopharma Inc | 31.38m | -1.91bn | 19.29bn | 34.00 | -- | 8.96 | -- | 614.52 | -94.41 | -94.41 | 1.53 | 86.36 | 0.015 | 0.00 | 0.2917 | 923,058.80 | -91.65 | -45.75 | -104.28 | -51.86 | 0.00 | 60.46 | -6,093.40 | -233.66 | 9.72 | -102.93 | 0.1442 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
Astena Holdings Co Ltd | 53.39bn | 2.09bn | 20.94bn | 1.40k | 9.71 | 0.7086 | 4.55 | 0.3923 | 52.62 | 52.62 | 1,341.82 | 721.11 | 0.7976 | 3.29 | 2.69 | 38,024,920.00 | 3.12 | 2.49 | 5.76 | 4.44 | 34.11 | 25.33 | 3.91 | 2.32 | 0.879 | 391.65 | 0.349 | 44.92 | 4.73 | -2.85 | 100.61 | -3.85 | 38.54 | 11.38 |
StemRIM Inc | 0.00 | -2.02bn | 21.90bn | 44.00 | -- | 2.46 | -- | -- | -32.98 | -32.98 | 0.00 | 144.57 | 0.00 | -- | -- | 0.00 | -20.44 | -8.34 | -20.74 | -8.49 | -- | -- | -- | -68.74 | 131.03 | -11,344.72 | 0.00 | -- | -100.00 | -- | -1,301.17 | -- | -4.35 | -- |
Fuso Pharmaceutical Industries Ltd | 57.72bn | 2.20bn | 25.06bn | 1.31k | 10.30 | 0.5978 | 5.60 | 0.4342 | 257.39 | 257.39 | 6,774.96 | 4,436.49 | 0.7581 | 3.07 | 2.33 | 44,163,730.00 | 2.89 | 1.91 | 4.97 | 3.09 | 26.58 | 26.92 | 3.81 | 2.69 | 0.9406 | 50.75 | 0.267 | 41.10 | 8.61 | 3.76 | -14.21 | 9.02 | 9.13 | -2.64 |
Fuji Pharma Co Ltd | 44.56bn | 6.36bn | 31.98bn | 1.62k | 4.94 | 0.6987 | 3.25 | 0.7177 | 261.79 | 261.79 | 1,833.31 | 1,849.15 | 0.5156 | 1.40 | 3.15 | 27,490,440.00 | 7.36 | 4.10 | 11.63 | 5.58 | 39.28 | 42.41 | 14.28 | 7.55 | 0.6276 | -- | 0.3912 | 31.17 | 15.42 | 1.52 | 27.41 | 0.3709 | 19.04 | 5.73 |
Daito Pharmaceutical Co Ltd | 47.40bn | 3.23bn | 33.29bn | 1.07k | 10.46 | 0.6379 | 4.85 | 0.7024 | 207.36 | 207.36 | 3,045.21 | 3,400.43 | 0.6178 | 1.86 | 2.76 | 44,294,390.00 | 3.90 | 6.27 | 5.08 | 8.24 | 20.28 | 22.65 | 6.32 | 8.47 | 1.29 | -- | 0.1891 | 19.59 | 3.98 | 2.66 | -8.47 | -1.27 | 11.37 | 11.67 |
Seikagaku Corp | 38.36bn | 2.02bn | 46.47bn | 988.00 | 22.15 | 0.593 | 13.86 | 1.21 | 36.93 | 36.93 | 703.10 | 1,379.48 | 0.4679 | 1.93 | 4.88 | 38,827,940.00 | 2.46 | 0.4261 | 2.66 | 0.4678 | 47.98 | 54.18 | 5.25 | 0.9814 | 4.53 | -- | 0.0051 | 465.78 | 8.24 | 4.99 | -2.24 | -0.5224 | 30.28 | 0.00 |
Data as of Nov 13 2024. Currency figures normalised to Fuji Pharma Co Ltd's reporting currency: Japanese Yen JPY
Holder | Shares | % Held |
---|---|---|
Nomura Asset Management Co., Ltd.as of 05 Aug 2024 | 548.00k | 2.21% |
The Vanguard Group, Inc.as of 02 Oct 2024 | 514.56k | 2.08% |
Dimensional Fund Advisors LPas of 03 Oct 2024 | 363.49k | 1.47% |
Nikko Asset Management Co., Ltd.as of 04 Oct 2024 | 271.60k | 1.10% |
Daiwa Asset Management Co. Ltd.as of 30 Sep 2024 | 209.50k | 0.85% |
Norges Bank Investment Managementas of 30 Jun 2024 | 103.60k | 0.42% |
Mitsubishi UFJ Asset Management Co., Ltd.as of 03 Oct 2024 | 92.10k | 0.37% |
Dimensional Fund Advisors Ltd.as of 03 Oct 2024 | 71.18k | 0.29% |
Mellon Investments Corp.as of 03 Oct 2024 | 67.70k | 0.27% |
Chibagin Asset Management Co. Ltd.as of 22 Jan 2024 | 59.30k | 0.24% |
More ▼
Data from 11 Mar 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.